Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 2/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481904 | 0.88 | NPY1R (0.41) | LTB4R2NPY1RCMKLR1EHMT2CTSL | |
| SCHEMBL6481243 | 0.86 | GHSR (0.34) | LTB4R2CMKLR1GHSRAGTR1 | |
| SCHEMBL6481453 | 0.86 | CTSS (0.38) | SIRT2GHSRCTSS | |
| SCHEMBL6495989 | 0.84 | MAPT (0.45) | CTSLHDAC1 | |
| SCHEMBL6483716 | 0.83 | NPY1R (0.38) | LTB4R2NPY1REHMT2GHSRCTSL | |
| SCHEMBL6482717 | 0.79 | HDAC1 (0.41) | EHMT2HDAC1 | |
| SCHEMBL4609709 | 0.79 | LTB4R2 (0.60) | LTB4R2HDAC1 | |
| SCHEMBL6480737 | 0.78 | LTB4R2 (0.35) | LTB4R2NPY1RAGTR1 | |
| SCHEMBL8793511 | 0.77 | NPY1R (0.45) | NPY1RCTSL | |
| SCHEMBL5489422 | 0.76 | LTB4R2 (0.42) | LTB4R2AGTR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | GLS2, STS, ABAT | SIRT2 1843/4885LTB4R2 2432/4885NPY1R 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.